L
Ling Wang
Researcher at Fujian Medical University
Publications - 9
Citations - 93
Ling Wang is an academic researcher from Fujian Medical University. The author has contributed to research in topics: Medicine & Epithelial–mesenchymal transition. The author has an hindex of 4, co-authored 6 publications receiving 67 citations.
Papers
More filters
Journal ArticleDOI
Extracellular Vesicles: A New Perspective in Tumor Therapy.
TL;DR: It is hoped that better knowledge and understanding of the extracellular vesicles will offer a wider range of effective therapeutic targets for experimental tumor research.
Journal ArticleDOI
Quadruple therapy for asymptomatic COVID-19 infection patients.
TL;DR: It should be noted that lopinavir/ritonavir tablets have many drug interactions and are the most likely drugs to cause hyperlipidemia and hyperglycemia in these two patients, but IFN-α2b is more effective in the early stage of virus infection.
Journal ArticleDOI
Ursolic Acid Attenuates TGF-β1-Induced Epithelial-Mesenchymal Transition in NSCLC by Targeting Integrin αVβ5/MMPs Signaling.
TL;DR: It is concluded that ursolic acid attenuated TGF-β1-induced EMT in H1975 cells and thus might be a promising therapeutic agent for treating NSCLC.
Journal Article
CCNA2 facilitates epithelial-to-mesenchymal transition via the integrin αvβ3 signaling in NSCLC.
TL;DR: Novel insights are provided into that CCNA2 represents a crucial regulator of NSCLC cells metastasis and suggests targeted treatment of CCNA 2-expressing cancer serves as a new therapeutic target for NSCLc.
Journal ArticleDOI
Impact of CYP2A6 gene polymorphism on the pharmacokinetics of dexmedetomidine for premedication.
Ling Wang,Shao-Ming Wang,Juan Qi,Rongguo Yu,Jie Zhuang,Boyang Zhuang,Yongming Lou,Junshan Ruan,Hong Ye,Fangfang Lin +9 more
TL;DR: In Chinese patients pretreated with dexmedetomidine, T1/2β was consistent with that published, but T 1/2α, V and Cl were lower, and it was unnecessary to consider the mutation when developing the precision regimen of dexmedETomidine.